| Title |
Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma
|
|---|---|
| Published in |
Cancer Management and Research, December 2012
|
| DOI | 10.2147/cmar.s38684 |
| Pubmed ID | |
| Authors |
Shunsuke Nojiri, Atsunori Kusakabe, Kei Fujiwara, Noboru Shinkai, Kentaro Matsuura, Etsuko Iio, Tomokatsu Miyaki, Tomoyuki Nomura, Satoshi Sobue, Hitoshi Sano, Izumi Hasegawa, Tomoyoshi Ohno, Yoshitsugu Takahashi, Etsuro Orito, Takashi Joh |
| Abstract |
Sorafenib has been approved in the indication of unresectable hepatocellular carcinoma, but there are many cases in which administration of the drug is discontinued due to severe side effects. In this study, we compared the characteristics of patients who continued and discontinued sorafenib. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 13 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 23% |
| Other | 3 | 23% |
| Librarian | 1 | 8% |
| Professor | 1 | 8% |
| Student > Bachelor | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 4 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 46% |
| Immunology and Microbiology | 1 | 8% |
| Biochemistry, Genetics and Molecular Biology | 1 | 8% |
| Unknown | 5 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 January 2013.
All research outputs
#20,110,957
of 25,584,565 outputs
Outputs from Cancer Management and Research
#1,017
of 2,067 outputs
Outputs of similar age
#219,972
of 286,730 outputs
Outputs of similar age from Cancer Management and Research
#2
of 6 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,067 research outputs from this source. They receive a mean Attention Score of 3.5. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,730 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.